Trial Profile
Vaccine Responses in Patients With B Cell Malignancies
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 10 Jan 2024
Price :
$35
*
At a glance
- Drugs Adjuvanted Hepatitis-B vaccine (Recombinant)-Dynavax (Primary) ; Elasomeran (Primary) ; GSK 137173A (Primary) ; GSK 1536489A (Primary) ; Influenza vaccine (Optaflu) (Primary) ; Influenza virus vaccine (Primary) ; Influenza virus vaccine (Afluria) (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Pneumococcal 23-valent vaccine Walvax Biotechnology (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections; Hepatitis B; Herpes zoster; Influenza virus infections; Pneumococcal infections
- Focus Pharmacodynamics
- 22 Aug 2023 Planned primary completion date changed from 9 Aug 2023 to 16 Aug 2024.
- 28 Oct 2022 Planned End Date changed from 16 Aug 2023 to 16 Aug 2024.
- 14 Sep 2022 Planned initiation date (estimated date for recruitment of the first subject) changed to 20 Sep 2022.